Boehringer Ingelheim Venture Fund — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Centauri Therapeuticscentauritherapeutics.cominFeb 2026
Centauri Therapeutics develops the Alphamer platform, a proprietary antibody recruiting molecule technology designed to redirect the immune system against disease targets.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAMR Action FundNCL Technology Ventures Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.